Ritonavir/Saquinavir plus One Nucleoside Reverse Transcriptase Inhibitor (NRTI) versus Indinavir plus Two Nrtis in Protease Inhibitor-Naive HIV-1-Infected Adults (Iris Study)

Carpenter C.C. , Cooper D.A. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Hammer S.M. , Hirsch M.S. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S. , Richman D.D. , Saag M.S. , Schechter M. , Schooley R.T. , Thompson M.A. , Vella S. , Yeni P.G. , & Volberding P.A. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283: 381–390.

Staszewski S. , Katlama C. , Harrer T. , Massip P. , Yeni P. , Cutrell A. , Tortell S.M. , Harrigan R.P. , Steel H. , Lanier R.E. , & Pearce G. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998; 12: F197–F202.

Staszewski S. , Morales-Ramirez J. , Tashima K.T. , Rachlis A. , Skiest D. , Stanford J. , Stryker R. , Johnson P. , Labriola D.F. , Farina D. , Manion D.J. , & Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team New England Journal of Medicine 1999; 341: 1865–1873.

Hsu A. , Granneman G.R. , & Bertz R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics 1998; 35: 275–291.

Noble S. , & Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93–112.

Fitzsimmons M.E. , & Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metabolism and Disposition 1997; 25: 256–266.

Hsu A. , Granneman G.R. , Cao G. , Carothers L. , el Shourbagy T. , Baroldi P. , Erdman K. , Brown F. , Sun E. , & Leonard J.M. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clinical Pharmacology and Therapeutics 1998; 63: 453–464.

Merry C. , Barry M.G. , Mulcahy F. , Ryan M. , Heavey J. , Tjia J.F. , Gibbons S.E. , Breckenridge A.M. , & Back D.J. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29–F33.

Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annual Review of Pharmacology and Toxicology 2000; 40: 649–674.

Roberts N.A. , Craig J.C. , & Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998; 12: 453–460.

Molla A. , Korneyeva M. , Gao Q. , Vasavanonda S. , Schipper P.J. , Mo H.M. , Markowitz M. , Chernyavskiy T. , Niu P. , Lyons N. , Hsu A. , Granneman G.R. , Ho D.D. , Boucher C.A. , Leonard J.M. , Norbeck D.W. , & Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2: 760–766.

Plosker G.L. , & Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999; 58: 1165–1203.

Gulick R.M. , Mellors J.W. , Havlir D. , Eron J.J. , Gonzalez C. , McMahon D. , Richman D.D. , Valentine F.T. , Jonas L. , Meibohm A. , Emini E.A. , & Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337: 734–739.

Hammer S.M. , Squires K.E. , Hughes M.D. , Grimes J.M. , Demeter L.M. , Currier J.S. , Eron J.J. Jr. , Feinberg J.E. , Balfour H.H. Jr. , Deyton L.R. , Chodakewitz J.A. , & Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 1997; 337: 725–733.

Katzenstein T.L. , Kirk O. , Pedersen C. , Lundgren J.D. , Nielsen H. , Obel N. , Nielsen C. , Mathiesen L.R. , & Gerstoft J. The Danish protease inhibitor study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 2000; 182: 744–750.

Kirk O. , Katzenstein T.L. , Gerstoft J. , Mathiesen L. , Nielsen H. , Pedersen C. , & Lundgren J.D. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999; 13: F9–F16.

de Mendoza C. , Soriano V. , Perez-Olmeda M. , Rodes B. , Casas E. , & Gonzalez-Lahoz J. Different outcomes in patients achieving complete or partial viral load suppression on anti-retroviral therapy. Journal of Human Virology 1999; 2: 344–349.

Murray J.S. , Elashoff M.R. , Iacono-Connors L.C. , Cvetkovich T.A. , & Struble K.A. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13: 797–804.

Cameron D.W. , Japour A.J. , Xu Y. , Hsu A. , Mellors J. , Farthing C. , Cohen C. , Poretz D. , Markowitz M. , Follansbee S. , Angel J.B. , McMahon D. , Ho D. , Devanarayan V. , Rode R. , Salgo M. , Kempf D.J. , Granneman R. , Leonard J.M. , & Sun E. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13: 213–224.

Gisolf E.H. , Jurriaans S. , Pelgrom J. , van Wanzeele F. , van der Ende M.E. , Brinkman K. , Borst M.J. , de Wolf F. , Japour A.J. , & Danner S.A. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 2000; 14: 405–413.

Bonfanti P. , Valsecchi L. , Parazzini F. , Carradori S. , Pusterla L. , Fortuna P. , Timillero L. , Alessi F. , Ghiselli G. , Gabbuti A. , Di Cintio E. , Martinelli C. , Faggion I. , Landonio S. , & Quirino T. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. Journal of Acquired Immune Deficiency Syndromes 2000; 23: 236–245.

d'Arminio M.A. , Lepri A.C. , Rezza G. , Pezzotti P. , Antinori A. , Phillips A.N. , Angarano G. , Colangeli V. , De Luca A. , Ippolito G. , Caggese L. , Soscia F. , Filice G. , Gritti F. , Narciso P. , Tirelli U. , & Moroni M. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14: 499–507.

Spilker B. Statistical issues. In Guide to clinical trials, 1991; pp. 498–500. Edited by Spilker B. New York: Raven Press.

Ioannidis J.P. , Bassett R. , Hughes M.D. , Volberding P.A. , Sacks H.S. , & Lau J. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997; 16: 22–30.